Hepatitis C virus-induced myeloid-derived suppressor cells regulate T-cell differentiation and function via the signal transducer and activator of transcription 3 pathway

Immunology

Volumn 148, Issue 4, 2016, Pages 377-386

  Ren, Jun P ^a   Zhao, Juan ^a   Dai, Jun ^a   Griffin, Jeddidiah W D ^a   Wang, Ling ^a   Wu, Xiao Y ^a   Morrison, Zheng D ^a   Li, Guang Y ^a   El Gazzar, Mohamed ^a   Ning, Shun B ^a   Moorman, Jonathan P ^a,b   Yao, Zhi Q ^a,b  

^a East Tennessee State University   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

hepatitis C virus; interleukin 10; myeloid derived suppressor cells; regulatory T cells; signal transducer and activator of transcription 3

Indexed keywords

CD11B ANTIGEN; CD14 ANTIGEN; CD33 ANTIGEN; CD4 ANTIGEN; CORE PROTEIN; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL FUNCTION; CELL ISOLATION; CELL MATURATION; CHRONIC HEPATITIS C; CONTROLLED STUDY; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; T LYMPHOCYTE;

EID: 84978476478     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12616     Document Type: Article

References (48)

1. Park SH, Rehermann B. Immune responses to HCV and other hepatitis viruses. Immunity 2014; 40:13–24.
2. Rosen HR. Emerging concepts in immunity to hepatitis C virus infection. J Clin Invest 2013; 123:4121–30.
3. Au JS, Pockros PJ. Novel therapeutic approaches for hepatitis C. Clin Pharmacol Ther 2014; 95:78–88.
4. Manns MP, von Hahn T. Novel therapies for hepatitis C – one pill fits all? Nat Rev Drug Discov 2013; 12:595–610.
5. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182:4499–506.
6. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162–74.
7. Dai J, El Gazzar M, Li GY, Moorman JP, Yao ZQ. Myeloid-derived suppressor cells: paradoxical roles in infection and immunity. J Innate Immun 2014; 7:116–26.
8. Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol 2009; 182:5693–701.
9. + T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol 2010; 136:35–45.
10. hi and overexpress CD80, CD83, and DC-sign. Cancer Res 2010; 70:4335–45.
11. Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte–macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007; 25:2546–53.
12. + T cells. Gastroenterology 2008; 135:234–43.
13. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012; 18:1254–61.
14. Vasquez-Dunddel D, Pan F, Zeng Q, Gorbounov M, Albesiano E, Fu J et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest 2013; 123:1580–9.
15. lo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood 2014; 124:750–60.
16. Chen S, Akbar SM, Abe M, Hiasa Y, Onji M. Immunosuppressive functions of hepatic myeloid-derived suppressor cells of normal mice and in a murine model of chronic hepatitis B virus. Clin Exp Immunol 2011; 166:134–42.
17. Huang A, Zhang B, Yan WW, Wang B, Wei HF, Zhang F et al. Myeloid-derived suppressor cells regulate immune response in patients with chronic hepatitis B virus infection through PD-1-induced IL-10. J Immunol 2014; 193:5461–9.
18. Vollbrechi T, Striner R, Tufman A, Roider J, Huber RM, Bogner JR et al. Chronic progressive HIV-1 infection is associated with elevated levels of myeloid-derived suppressor cells. AIDS 2012; 26:F31–7.
19. Macatangay BJ, Landay AL, Rinaldo CR. MDSC: a new player in HIV immunopathogenesis. AIDS 2012; 26:1567–9.
20. Qin A, Cai W, Pan T, Wu K, Yang Q, Wang N et al. Expansion of monocytic myeloid-derived suppressor cells dampens T cell function in HIV-1-seropositive individuals. J Virol 2013; 87:1477–90.
21. Garg A, Spector SA. HIV type 1 gp120-induced expansion of myeloid derived suppressor cells is dependent on interleukin 6 and suppresses immunity. J Infect Dis 2014; 209: 441–51.
22. low/neg monocytes functionally similar to myeloid-derived suppressor cells during SIV and HIV infection. J Leukoc Biol 2012; 91:803–16.
23. Tacke RS, Lee HC, Goh C, Courtney J, Polyak SJ, Rosen HR et al. Myeloid suppressor cells induced by hepatitis C virus suppress T-cell responses through the production of reactive oxygen species. Hepatology 2012; 55:343–53.
24. + T cells in chronic hepatitis C patients. Mol Cells 2014; 37:66–73.
25. Cai W, Qin A, Guo P, Yan D, Hu F, Yang Q et al. Clinical significance and functional studies of myeloid-derived suppressor cells in chronic hepatitis C patients. J Clin Immunol 2013; 33:798–808.
26. Bowers NL, Helton ES, Huijbregts RP, Goepfert PA, Heath SL, Hel Z. Immune suppression by neutrophils in HIV-1 infection: role of PD-L1/PD-1 pathway. PLoS Pathog 2014; 10:e1003993.
27. Norris BA, Uebelhoer LS, Nakaya HI, Price AA, Grakoui A, Pulendran B. Chronic but not acute virus infection induces sustained expansion of myeloid suppressor cell numbers that inhibit viral-specific T cell immunity. Immunity 2013; 38:309–21.
28. Nonnenmann J, Stirner R, Roider J, Jung MC, Schrudl K, Bogner JR et al. Lack of significant elevation of myeloid-derived suppressor cells in peripheral blood of chronically hepatitis C virus-infected individuals. J Virol 2014; 88:7678–82.
29. Yao ZQ, Nguyen DT, Hiotellis AI, Hahn YS. Hepatitis C virus core protein inhibits human T lymphocyte responses by a complement-dependent regulatory pathway. J Immunol 2001; 167:5264–72.
30. + T cells leads to impaired activation of Lck and Akt. J Virol 2004; 78:6409–19.
31. Song H, Wang RX, Wang SM, Lin JY. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci USA 2005; 102:4700–5.
32. + Treg expansion. Am J Transplant 2013; 13:3123–31.
33. Moorman JP, Wang JM, Zhang Y, Ji XJ, Ma CJ, Wu XY et al. Tim-3 pathway controls regulatory and effector T cell balance during HCV infection. J Immunol 2012; 189:755–66.
34. + T-cell responses through overexpression of DUSP6. Hepatology 2015; 61:1163–73.
35. Tacke RS, Tosello-Trampont A, Nguyen V, Mullins DW, Hahn SH. Extracellular hepatitis C virus core protein activates STAT3 in human monocytes/macrophages/dendritic cells via an IL-6 autocrine pathway. J Biol Chem 2011; 286:10847–55.
36. Korrylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005; 11: 1314–21.
37. Jabłońska J, Pawłowski T, Laskus T, Zalewska M, Inglot M, Osowska S et al. The correlation between pretreatment cytokine expression patterns in peripheral blood mononuclear cells with chronic hepatitis C outcome. BMC Infect Dis 2015; 15:556.
38. Pawlowski T, Radkowski M, Małyszczak K, Inglot M, Zalewska M, Jablonska J et al. Depression and neuroticism in patients with chronic hepatitis C: correlation with peripheral blood mononuclear cells activation. J Clin Virol 2014; 60:105–11.
39. Jain MK, Adams-Huet B, Terekhova D, Kushner LE, Bedimo R, Li X et al. Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co-infected patients. J Viral Hepat 2015; 22:25–36.
40. Marinho R, Pinto R, Santos ML, de M. Evidence for prostaglandin-producing suppressor cells in HCV patients with normal ALT. Dig Dis Sci 2002; 47:556–61.
41. Waris G, Siddigui A. Hepatitis C virus stimulates the expression of cyclooxygenase-2 via oxidative stress: role of prostaglandin E2 in RNA replication. J Virol 2005; 79:9725–34.
42. Lu L, Wei L, Peng G, Mu Y, Wu K, Kang L et al. NS3 protein of hepatitis C virus regulates cyclooxygenase-2 expression through multiple signaling pathways. Virology 2008; 371:61–70.
43. Chen JH, Perry CJ, Tsui YC, Staron MM, Parish IA, Dominguez CX et al. Prostaglandin E2 and programmed cell death 1 signaling coordinately impair CTL function and survival during chronic viral infection. Nat Med 2015; 21:327–34.
44. Hart KM, Byrne KT, Molloy MJ, Usherwood EM, Berwin B. IL-10 immunomodulation of myeloid cells regulates a murine model of ovarian cancer. Front Immunol 2011; 2:29.
45. Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 2010; 185:2273–84.
46. Condamine T, Gabrilovich DI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol 2011; 32:19–25.
47. + regulatory T-cell development through the Tim-3/Gal-9 pathway. Eur J Immunol 2013; 43:458–67.
48. + regulatory T cells in chronic hepatitis C patients. Cell Mol Immunol 2015; 12:743–9.